Six-month clinical outcomes of the Tryton Side Branch Stent for the treatment of bifurcation lesions

Double bifurcation lesion treated with double Tryton Sidebranch Stent: first case report

The optimal percutaneous treatment strategy for coronary bifurcation lesions is still unknown. Several dedicated coronary bifurcation stents, such as the Tryton Side Branch Stent™ (Tryton Medical, Durham, NC) have been developed to improve clinical outcomes. We presented a double bifurcation lesion case treated with two Tryton sidebranch stents, with a single drug eluting stent covering the main vessel and both bifurcations.

Placement of Tryton Side Branch Stent only; a new treatment strategy for Medina 0,0,1 coronary bifurcation lesions

OBJECTIVES

We propose a new treatment strategy of Medina 0,0,1 bifurcation lesions using a dedicated side branch stent alone (Tryton Side Branch Stent™) without additional main branch stenting, with the advantage of an optimal ostial side branch coverage without the disadvantage of an excessive amount of metal in the main branch.

BACKGROUND

Medina 0,0,1 lesions are relatively rare and there is no consensus on treatment strategy. Several previous techniques have been described, all with considerable disadvantages.

METHODS

Between October 2009 and November 2011, 12 patients with Medina 0,0,1 lesions treated with Tryton alone were included. Clinical outcomes were reported as all-cause mortality, recurrent myocardial infarction (MI), target vessel revascularization (TVR), target lesion revascularization (TLR), and target vessel failure (TVF; defined as the composite of all-cause mortality, MI, and TVR). Procedural success was defined as successful stent placement with residual stenosis <30%, postprocedural TIMI 3 flow, and no in-hospital TVF.

RESULTS

Mean age was 64 years. Median side branch reference vessel diameter was 2.6 [2.5-3.0] mm (median stenosis 75%). Procedural success was 100%. Median clinical follow-up duration was 868 [470-906] days with just one of the patients suffering from a late adverse clinical outcome: TLR at 427 days, resulting in TVF, TVR, and TLR rates of 8.3%.

CONCLUSION

Treatment of Medina 0,0,1 lesions with the Tryton stent alone was associated with a 100% procedural success and only one late clinical adverse event (median follow-up of 868 days). These first positive results need to be confirmed in larger prospective randomized studies.